Compare Aptiv PLC (APTV) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs IDEXX Laboratories, Inc. — how do they compare? Aptiv PLC trades at $49.58 (market cap $10.30B), while IDEXX Laboratories, Inc. trades at $573.59 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.5× Aptiv PLC's market cap. Which is the better fit depends on your goals.
| APTV | IDXX | |
|---|---|---|
Market Cap | $10.30B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $766.68 |
52-Week Low | $46.30 | $526.44 |
Enterprise Value | $15.23B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $49.81, up 0.52% on the day, but remains under pressure following a lowered 2026 outlook despite recent earnings beats. Technical indicators are bearish, with the stock near support at $49. Fundamentally, revenue grew to $20.40B in 2025, but net income margin compressed to 1.07%, reflecting margin pressure. The company faces headwinds from China demand weakness and program delays, as highlighted in recent news.
The investment case balances a low valuation (P/E 22.45, P/S 0.52) and strong analyst buy ratings (63.64% buy) against near-term execution risks and cash flow volatility. Upside to the $70.09 consensus target exists if operational improvements materialize, but investors must weigh guidance cuts and competitive threats in the auto sector.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
